Sibel Ozdemir | Pharmacology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Sibel Ozdemir — Yunus Emre State Hospital, Turkey

Sibel Ozdemir
Affiliation Yunus Emre State Hospital
Country Turkey
Scopus ID 60749146700
Subject Area Pharmacology
Event Health Scientists Awards
ORCID 0009-0003-4671-0964

Sibel Ozdemir is a researcher associated with Yunus Emre State Hospital whose recent scholarly work connects neurology with pharmacological investigation. Published studies have examined antiseizure medicines, experimental seizure models, medication combinations, and potential interactions involving clopidogrel, valproic acid, and levetiracetam. [1] [2]

Abstract

Sibel Ozdemir is a researcher affiliated with Yunus Emre State Hospital in Turkey whose documented work addresses pharmacology, neurology, and experimental seizure research. Her recent publications examine interactions between antiplatelet and antiseizure medicines and pharmacological effects in experimental models. This profile summarizes her research themes, publications, and recognition context in research.

Keywords

Epilepsy, valproic acid, levetiracetam, clopidogrel, pentylenetetrazol, freezing behavior, antiseizure medicines, anticonvulsant efficacy, experimental seizure models, behavioral effects, drug interactions, neurology, pharmacology, and clinical pharmacology. These terms reflect the themes identified in her recent research publications. [1] [2]

Introduction

Sibel Ozdemir is affiliated with the Department of Neurology at Yunus Emre State Hospital, Eskişehir, Türkiye. Her recent scholarly record includes investigations involving antiseizure medicines, drug interactions, and neurological models. These studies connect clinical neurology with pharmacological questions concerning treatment combinations and biological responses in experimental research settings. [1] [2]

Research Profile

Sibel Ozdemir’s documented research profile centers on neurology and pharmacology, with publications involving antiseizure therapy, experimental seizure models, and medication interactions. PubMed records identify her ORCID as 0009-0003-4671-0964 and associate recent work with Yunus Emre State Hospital. The available evidence supports a clinically oriented pharmacological research profile in clinical practice. [1]

Research Contributions

Sibel Ozdemir contributes to research examining pharmacological effects in neurological conditions. A 2026 study evaluated clopidogrel alongside valproic acid and levetiracetam in a pentylenetetrazol-induced seizure model, while another study examined differential effects of valproic acid and levetiracetam on freezing behavior. These studies address medication efficacy and drug interactions in pharmacology. [1] [2]

Publications

Sibel Ozdemir is listed as an author on publications concerning antiseizure pharmacology and neurological experimental models. Her 2026 International Journal of Molecular Sciences article investigated clopidogrel with valproic acid and levetiracetam, while a 2026 Journal of Biotechnology and Strategic Health Research article examined valproic acid and levetiracetam effects in rats. [1] [2]

Research Impact

Sibel Ozdemir’s research has potential relevance to pharmacological decision-making by investigating how neurological medicines behave in experimental combinations. The documented studies provide evidence about antiseizure efficacy and medication interactions, while their experimental designs also illustrate translational questions that may require further clinical investigation before broader conclusions are drawn. [1] [2]

Award Suitability

Sibel Ozdemir’s publication activity aligns with an Innovative Research Award profile through its focus on pharmacological questions in neurological research and experimental models. The publications demonstrate investigation of drug combinations and antiseizure effects. Award recognition should consider originality, methodological contribution, publication record, and relevance of the submitted research evidence overall. [1] [2]

Conclusion

Sibel Ozdemir’s available scholarly record presents a research trajectory connecting clinical neurology with pharmacology and experimental seizure research. Her recent publications provide documented evidence of work on antiseizure medicines and drug interactions. Continued publication, independent validation, and clinical translation would further clarify the broader significance of these research contributions today. [1] [2]

References

    1. Özdemir, S., Bolayır, E., & Şahin İnan, Z. D. (2026). Effects of Clopidogrel on the Anticonvulsant Efficacy of Valproic Acid and Levetiracetam in a PTZ-Induced Seizure Model. International Journal of Molecular Sciences, 27(14), 6415.
      https://doi.org/10.3390/ijms27146415
    2. Gürkan, İ. M., Demir Cevizlidere, B., Çalişkan, S., Özdemir, S., & Özdemir, H. (2026). Effects of nano-hydroxyapatite-coated PRF on gingiva-derived mesenchymal stem cells: In vitro study. International Journal of Molecular Sciences, 27(13), 5736.
      https://doi.org/10.3390/ijms27135736
    3. ORCID. (n.d.). ORCID record: Sibel Ozdemir, ORCID 0009-0003-4671-0964.
      https://orcid.org/0009-0003-4671-0964
    4. Elsevier. (n.d.). Scopus author details: Sibel Ozdemir, Author ID 60749146700. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=60749146700

Raphael Duval | Pharmacology | Research Excellence Award

Published on by Health Scientists

Prof. Dr. Raphael Duval | Pharmacology | Research Excellence Award

Dean | Université de Lorraine | France

Raphaël E. Duval is a senior academic leader and clinical microbiologist serving as Professor and Dean of the Faculty of Pharmacy at Université de Lorraine, France. His expertise spans infectiology, virology, cellular biology, and pharmaceutical sciences, with a strong focus on the discovery and development of innovative anti-infective and anticancer therapeutic agents. His research is widely disseminated through international peer-reviewed journals, scholarly book chapters, patents, and invited scientific communications, reflecting significant academic influence and citation impact. He actively collaborates with multidisciplinary teams across academia and industry at national and international levels. Recognized through prestigious scientific awards and fellowships, his work contributes to advancing therapeutic innovation, strengthening infectious disease management, and addressing major public health challenges with meaningful societal and clinical impact. He has 4909 citations from 98 documents with an h-index of 34.

Citation Metrics (Scopus)

4909
3500
2000
1000
0

Citations

4,909

Documents

98

h-index

34

Citations

Documents

h-index

View Google Scholar Profile
 View Scopus Profile
 View Orcid Profile

Featured Publications

Amin Hasanvand | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Amin Hasanvand | Pharmacology | Best Researcher Award

Associate Professor | Lorestan University | Iran

Dr. Amin Hasanvand, Associate Professor in the Department of Pharmacology at Lorestan University of Medical Sciences, is an accomplished Iranian pharmacologist and biomedical scientist whose career reflects excellence in research, teaching, and leadership in health sciences. He earned his Ph.D. in pharmacology from Tehran University of Medical Sciences in 2016, with a doctoral thesis focused on the AMPK signaling pathway and its role in diabetic neuropathy, and has since developed a robust academic profile. His research interests span pharmacology, diabetes, nephropharmacology, inflammation, neuropathy, and neuroscience, with particular focus on AMPK-dependent mechanisms, metformin, gut microbiome modulation, and novel strategies for neuropathic pain management. Over the years, Dr. Hasanvand has published more than 50 peer-reviewed articles in SCI and Scopus-indexed journals, authored two academic books titled Medical Pharmacology Education and Antibiotics: Mechanisms of Action and Clinical Applications, and contributed to over 40 completed research projects, while actively mentoring medical and pharmacy students. He also serves as Editor of the Herbal Medicine Journal and as an editorial board member of Annals of Pharmacology and Immunopathologia Persa, alongside being a reviewer for leading international journals such as Journal of Neuroimmune Pharmacology, Cancer Control, and Obesity Reviews. In recognition of his impactful contributions, Dr. Hasanvand has been honored seven times as the top researcher at his university and was ranked among the world’s top 2% most influential scientists in 2023. His distinguished career reflects an enduring commitment to advancing pharmacological sciences and improving health outcomes through research, innovation, and education. He has 809 citations from 38 documents with an h-index of 14.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Mir, S., Abbaszadeh, A., Hasanpour Dehkordi, A., & Hasanvand, A. (2019). Metformin and its anti-inflammatory and anti-oxidative effects; new concepts. Journal of Renal Injury Prevention.

2. Hasanvand, A., Kharazmkia, A., Mir, S., Khorramabadi, R. M., & Darabi, S. (2018). Ameliorative effect of ferulic acid on gentamicin-induced nephrotoxicity in a rat model; role of antioxidant effects. Journal of Renal Injury Prevention.

3. Khorramabadi, R. M., Amanolahi Baharvand, P., Pirzadroozbahani, N., Hasanvand, A., Kharazmkia, A., Goudarzi, M., Mir, S., & Ahmadizar, F. (2018). Evaluation of the antioxidant effects of zolpidem in the rat model of cisplatin-induced nephrotoxicity. Journal of Renal Injury Prevention.

4. Hasanvand, A., Amini-Khoei, H., Jahanabadi, S., Hadian, M.-R., Abdollahi, A., Tavangar, S. M., Mehr, S. E., & Dehpour, A. R. (2018). Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through activation of AMPK signaling pathway. Journal of Nephropathology.

5. Abbaszadeh, A., Koushki, S., Koushki, S., Eskandarzadeh, M., & Hasanvand, A. (2018). Metformin; a mini-review to its antioxidative and anti-inflammatory properties. Journal of Renal Injury Prevention.

6. Babaeenezhad, E., & Hasanvand, A. (2018). Renoprotective impacts of metformin with insulin in type 1 diabetes; role of its antioxidant efficacy. Journal of Nephropathology.